ispecimen inc - ISPC

ISPC

Close Chg Chg %
0.31 0.03 8.27%

Closed Market

0.34

+0.03 (8.27%)

Volume: 2.43M

Last Updated:

Jan 13, 2026, 4:00 PM EDT

Company Overview: ispecimen inc - ISPC

ISPC Key Data

Open

$0.30

Day Range

0.29 - 0.37

52 Week Range

0.26 - 3.38

Market Cap

$3.11M

Shares Outstanding

10.04M

Public Float

10.00M

Beta

1.83

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$7.89

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.41M

 

ISPC Performance

1 Week
 
12.53%
 
1 Month
 
-25.10%
 
3 Months
 
-54.77%
 
1 Year
 
-85.86%
 
5 Years
 
N/A
 

ISPC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About ispecimen inc - ISPC

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

ISPC At a Glance

iSpecimen, Inc.
8 Cabot Road
Woburn, Massachusetts 01801
Phone 1-781-301-6700 Revenue 9.29M
Industry Miscellaneous Commercial Services Net Income -12,497,805.00
Sector Commercial Services Employees 24
Fiscal Year-end 12 / 2025
View SEC Filings

ISPC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.203
Price to Book Ratio 1.361
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.032
Enterprise Value to Sales 0.035
Total Debt to Enterprise Value 0.972

ISPC Efficiency

Revenue/Employee 387,129.792
Income Per Employee -520,741.875
Receivables Turnover 6.431
Total Asset Turnover 0.738

ISPC Liquidity

Current Ratio 0.622
Quick Ratio 0.622
Cash Ratio 0.326

ISPC Profitability

Gross Margin 20.296
Operating Margin -133.468
Pretax Margin -134.514
Net Margin -134.514
Return on Assets -99.31
Return on Equity -191.507
Return on Total Capital -344.941
Return on Invested Capital -187.233

ISPC Capital Structure

Total Debt to Total Equity 9.428
Total Debt to Total Capital 8.616
Total Debt to Total Assets 3.339
Long-Term Debt to Equity 8.118
Long-Term Debt to Total Capital 7.419
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ispecimen Inc - ISPC

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
11.14M 10.40M 9.93M 9.29M
Sales Growth
+36.06% -6.58% -4.56% -6.42%
Cost of Goods Sold (COGS) incl D&A
6.25M 5.96M 6.89M 7.41M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.00M 1.21M 2.07M 2.29M
Depreciation
45.36K 22.43K 117.54K 65.71K
Amortization of Intangibles
958.64K 1.18M 1.95M 2.23M
COGS Growth
+74.40% -4.65% +15.49% +7.54%
Gross Income
4.88M 4.44M 3.04M 1.89M
Gross Income Growth
+6.17% -9.06% -31.48% -38.02%
Gross Profit Margin
+43.85% +42.68% +30.64% +20.30%
2021 2022 2023 2024 5-year trend
SG&A Expense
10.81M 14.63M 14.21M 14.29M
Research & Development
2.41M 3.46M 4.60M 2.03M
Other SG&A
8.40M 11.17M 9.61M 12.26M
SGA Growth
+54.28% +35.33% -2.83% +0.53%
Other Operating Expense
- - - -
-
Unusual Expense
- - 900.75K 327.39K
-
EBIT after Unusual Expense
(6.83M) (10.19M) (11.17M) (12.73M)
Non Operating Income/Expense
(33.13K) 179.13K 85.86K 404.01K
Non-Operating Interest Income
11.40K 169.34K 339.75K 44.13K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.10M 238.96K 16.00K 173.77K
Interest Expense Growth
+0.28% -88.64% -93.30% +986.00%
Gross Interest Expense
2.10M 238.96K 16.00K 173.77K
Interest Capitalized
- - - -
-
Pretax Income
(8.96M) (10.25M) (11.10M) (12.50M)
Pretax Income Growth
-92.64% -14.33% -8.33% -12.60%
Pretax Margin
-80.48% -98.50% -111.80% -134.51%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(8.96M) (10.25M) (11.10M) (12.50M)
Minority Interest Expense
- - - -
-
Net Income
(8.96M) (10.25M) (11.10M) (12.50M)
Net Income Growth
-92.64% -14.33% -8.33% -12.60%
Net Margin Growth
-80.48% -98.50% -111.80% -134.51%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(8.96M) (10.25M) (11.10M) (12.50M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(8.96M) (10.25M) (11.10M) (12.50M)
EPS (Basic)
-20.5228 -23.1696 -24.5528 -17.5814
EPS (Basic) Growth
-44.82% -12.90% -5.97% +28.39%
Basic Shares Outstanding
436.67K 442.22K 452.07K 710.85K
EPS (Diluted)
-20.5228 -23.1696 -24.5528 -17.5814
EPS (Diluted) Growth
-44.82% -12.90% -5.97% +28.39%
Diluted Shares Outstanding
436.67K 442.22K 452.07K 710.85K
EBITDA
(4.92M) (8.98M) (9.10M) (10.11M)
EBITDA Growth
-210.16% -82.49% -1.37% -11.01%
EBITDA Margin
-44.20% -86.34% -91.70% -108.77%

Ispecimen Inc in the News